Anthem Biosciences Q1 FY27: Revenue down 23% YoY, PBT drops

Q1 FY27 result: a weaker quarter on headline numbers

Anthem Biosciences Limited reported a softer operational quarter for Q1 FY27 (quarter ended 30 June 2026), with declines on both year-on-year and quarter-on-quarter comparisons in key consolidated metrics. The company announced its consolidated financial results on Tuesday, and the figures point to a sharp sequential drop in revenue from operations compared with the March 2026 quarter.

Alongside the near-term contraction, the broader narrative in the company’s ecosystem includes developments that are not directly reflected in quarterly earnings, such as a credit rating upgrade by ICRA and large block deals involving global institutions, as referenced in the market snapshot. Investors typically track such signals for what they may indicate about funding access and institutional interest, even as quarterly performance remains the immediate driver.

Consolidated performance: revenue, profit, and expenses

For the quarter ended 30 June 2026, Anthem Biosciences reported consolidated revenue from operations of ₹418.22 crore. Consolidated net profit for the same period stood at ₹119.94 crore.

Profit before tax (PBT) came in at ₹144.58 crore. Total expenses were ₹298.53 crore for the quarter, lower than both the preceding quarter and the year-ago quarter as per the company’s disclosure.

The quarter’s data set also includes a commonly-circulated snapshot figure of around ₹384 crore for Q1 revenue, which aligns closely with the company’s standalone revenue reported at ₹383.84 crore for Q1 FY27, while the consolidated revenue from operations was ₹418.22 crore.

Sequential trend: sharp QoQ drop from March 2026

On a quarter-on-quarter basis, consolidated revenue from operations fell 31.54% from ₹610.94 crore in the quarter ended 31 March 2026 to ₹418.22 crore in the June 2026 quarter.

PBT also declined materially versus the March quarter, coming down to ₹144.58 crore from ₹277.92 crore. The company’s expense line moved lower as well, with total expenses at ₹298.53 crore versus ₹385.22 crore in the preceding quarter.

This combination indicates that while cost reduction helped, it did not fully offset the impact of the lower revenue base on profitability in Q1 FY27.

Year-on-year trend: revenue down 22.58% from June 2025

Year-on-year, consolidated revenue from operations declined 22.58%, from ₹540.21 crore in the quarter ended 30 June 2025 to ₹418.22 crore in Q1 FY27.

PBT was also lower compared with the year-ago quarter, easing to ₹144.58 crore from ₹186.25 crore. Total expenses decreased to ₹298.53 crore from ₹376.77 crore over the same period, which helped contain the profitability decline, but the reduction in revenue still translated into weaker absolute profit.

Segment mix: CRDMO remains the largest contributor

Anthem’s revenue composition for the quarter shows the Contract Research and Development and Manufacturing Organisation (CRDMO) business continuing to carry the bulk of the top line. The CRDMO segment contributed ₹340.80 crore to total revenue in the June 2026 quarter.

The Speciality Ingredients segment generated ₹77.42 crore in revenue for the quarter. Together, these two segment figures sum to ₹418.22 crore, matching the consolidated revenue from operations reported for Q1 FY27.

The segment split highlights that performance in the CRDMO business can heavily influence overall outcomes, given its weight in the revenue mix.

Cost line detail: employee expenses moved up

One notable item in the cost structure was employee benefit expenses, which rose to ₹78.84 crore in Q1 FY27. This was higher than ₹72.48 crore in the preceding quarter and ₹72.03 crore in the year-ago quarter.

At the aggregate level, total expenses still fell, but the increase in employee benefit expenses is a data point investors often monitor, especially in R&D-heavy and specialised manufacturing businesses where talent costs can be structural.

Standalone snapshot: revenue at ₹383.84 crore, profit at ₹102.01 crore

On a standalone basis, Anthem reported Q1 FY27 revenue of ₹383.84 crore and profit of ₹102.01 crore. A separate market snapshot compared standalone net profit and revenue versus the year-ago period and highlighted a contraction.

The snapshot also states consolidated Q1 revenue at ₹384 crore (which aligns closely with standalone revenue) and notes standalone profit of ₹102 crore. It further compares Q1 FY27 against Q1 FY26, stating that consolidated Q1 revenue fell from ₹538 crore to ₹384 crore, and standalone net profit fell from ₹148 crore to ₹102 crore, alongside derived year-on-year decline percentages.

Governance, audit review, and ESOP-related equity changes

The company’s paid-up equity share capital as of 30 June 2026 was disclosed at ₹112.68 crore. During the quarter, Anthem allotted 1,670,909 fully paid-up equity shares under its ESOP Scheme 2024.

The filing also references an unmodified audit opinion from K.P. Rao & Co., which supports confidence in the reported financial statements. The results were reviewed by the audit committee and approved by the board on 21 July 2026, as per the details provided.

Subsidiary contribution noted in disclosures

Anthem’s subsidiary, NeoAnthem Lifesciences Private Limited, contributed ₹35.81 crore in revenue before consolidation, as stated in the provided text. While this number alone does not define consolidated performance, such line items help investors understand where incremental revenue is coming from within the group.

Stock and market signals mentioned alongside results

In a separate market update included in the text, Anthem Biosciences’ share price was reported to have moved up 0.92% from its previous close of ₹628.25 to a last traded price of ₹634.00.

The same information bundle also mentions a P/E of 87.5 and a market cap figure of ₹43,999 (unit not specified in the text). Additionally, it notes that the trading window was closed until 23 July ahead of the board meeting on 21 July 2026 to approve Q1 FY27 results.

Key numbers at a glance

Segment and selected expense breakup

What investors typically track from here

The Q1 FY27 print places attention on how Anthem manages volumes, pricing, and mix within CRDMO, given its outsized share of revenue. The sequential drop from the March quarter is significant in magnitude, even though expenses also moderated.

Separately, the mention of a credit rating upgrade by ICRA and institutional block deals is likely to keep investor focus on balance sheet access and ownership trends, but these factors do not replace the need for sustained operating execution across quarters.

Conclusion

Anthem Biosciences started FY27 with lower consolidated revenue from operations of ₹418.22 crore and consolidated net profit of ₹119.94 crore, while standalone profit was reported at ₹102.01 crore. Segment data shows CRDMO remained the primary revenue engine in the quarter. The next key checkpoints for investors will be subsequent quarterly updates and any further disclosures tied to operating momentum and segment performance.